Naltrexone is a pure opioid receptor antagonist utilized principally for the treatment of alcohol and opioid dependence. As an opioid receptor antagonist, naltrexone competitively binds to mu-opioid receptor (MOR) and kappa-opioid receptor (KOR) sites with higher affinity than opioid agonists, thereby attenuating receptor activation. Should an individual administer an opioid agonist (e.g. morphine) while taking …
Maxalt (Rizatriptan) is a pharmaceutical medication engineered by Merck & Co. for the treatment of migraine headaches (with or without aura). It received FDA approval in 1998 as an abortive antimigraine intervention and is chemically classified as a second-generation triptan (tryptamine-based). Analogous to other triptans, Rizatriptan remains ineffective as a migraine prophylactic, however, it is …
Relpax (Eletriptan) is a medication manufactured by Pfizer Inc. for the acute treatment of migraine headaches (with or without aura) in adults. It was initially approved by the FDA in 2002 and is regarded as a highly effective abortive agent, engineered to attenuate already-occurring migraine attacks. Chemically, Relpax is classified as a second generation triptan …
Requip (Ropinirole) is a drug initially approved in 1997 by the United States FDA for the treatment of [early or advanced-stage] idiopathic Parkinson’s disease. In the management of Parkinson’s disease, Requip can be utilized either as: a standalone agent or as an adjunct to L-DOPA. After its initial approval for the attenuation of Parkinson’s symptoms, …
Mirapex (Pramipexole) is a medication that was approved by the FDA in 1997 for the treatment of idiopathic (early-stage and advanced) Parkinson’s disease. Analysis of the drug’s pharmacodynamics reveals its function as a mixed partial/full dopamine agonist, with highest affinity for: D3 receptors, D2 receptors (D2S and D2L), and D4 receptors (in that order). To …
Modafinil (brand name “Provigil”) is a blockbuster eugeroic drug synthesized by Cephalon Pharmaceuticals (now Teva) and approved in 1998 for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy. It was since approved for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea, as well as to normalize circadian rhythms in diagnoses …
Adrafinil (Olmifon) is a eugeroic agent originally synthesized in the 1970s by chemists at Group Lafon, a pharmaceutical company based in France. Following its synthesis, researchers discovered that adrafinil induced wakefulness in humans, and by the mid-1980s, it was being marketed as an experimental treatment for narcolepsy. Though its exact pharmacodynamics aren’t fully elucidated, adrafinil …